Abstract

Despite the promising introduction of Glucagon-like Peptide-1 (GLP-1) analogs in the Indian market for managing diabetes and obesity, their uptake remains limited due to several factors: high costs, lack of outpatient insurance coverage, side effects, limited long-term data on cardiovascular and renal safety, and healthcare professionals' reluctance to prescribe them. This study aims to explore these barriers and propose innovative strategies to enhance the adoption of GLP-1 analogs in India. By applying Rogers' Diffusion of Innovations theory, the research will analyze the adoption process and develop targeted strategies to overcome identified challenges, ultimately benefiting a significant segment of the population struggling with diabetes and obesity.

Introduction

Background and Research Setting

GLP-1 analogs have been introduced in the Indian market with significant promise for managing diabetes and obesity. However, their adoption is hindered by several obstacles, including high costs, lack of insurance coverage, side effects, drug availability, and healthcare professionals' (HCPs) reluctance to prescribe them (Wang et al., 2023). In a country where many patients are self-paying, these issues are exacerbated, leading to limited uptake of these innovative medications.

Motivation for This Research

The global type 2 diabetes drugs market is projected to reach over US$100 billion over the next decade, with diabetes-related health expenditure estimated to rise to $1054 billion by 2045 (Lancet, 2023). In India, the prevalence of diabetes is exacerbated by factors such as sedentary lifestyles, stress, and genetic predisposition (Diabetes, Metabolic Syndrome and Obesity, 2020; Indian Journal of Ophthalmology, 2021). Despite the availability of innovative medications like GLP-1 analogs, their adoption is hindered by factors such as high pricing, inadequate insurance schemes, and limited awareness. This research seeks to design innovative pricing models to enhance the accessibility of GLP-1 analogs in the Indian market, thereby enabling the population to effectively combat diabetes and its associated complications.

Research Problem

Rogers' Diffusion of Innovations theory will guide this study in understanding the adoption process of GLP-1 antagonists. The theory outlines five categories of adopters: innovators, early adopters, early majority, late majority, and laggards (Dearing & Cox, 2018). By applying this model, the research will explore how each group perceives and reacts to GLP-1 antagonists, identifying specific barriers and facilitators for each category.

Literature Review

Barriers to Adoption

Despite the growing prevalence of diabetes and obesity in the Indian population, there remains a significant challenge in effectively managing these conditions. While GLP-1 agonists show promise as effective treatments for diabetes, their adoption in the Indian market is hindered by several challenges (Das et al., 2022; Ghosal et al., 2016).

Cost and Pricing Challenges

One major hurdle to the early adoption of newer drugs in the Indian market is their pricing structure. Multinational corporations must develop innovative strategies to make these products more accessible to a larger portion of the population without compromising on affordability (Mohan et al., 2013; Patel et al., 2020).

Awareness and Prescribing Practices

There exists a notable lack of awareness among healthcare professionals regarding these innovative medications, potentially leading to underutilization and suboptimal prescribing practices (Singh et al., 2018).

Research Objectives

Assessment of Current Challenges and Barriers

  • Identify the perceived benefits of GLP-1 agonists compared to existing treatments.
  • Assess how well GLP-1 agonists align with existing practices and patient lifestyles.
  • Determine the perceived difficulty in understanding and using GLP-1 agonists.

Exploration of Perceptions and Attitudes

  • Evaluate the extent to which GLP-1 agonists can be experimented with on a limited basis.
  • Investigate the visibility of the benefits of GLP-1 agonists to healthcare providers and patients.

Investigation of Reluctance and Resistance Factors

  • Identify the characteristics of healthcare providers and patients who are willing to try new treatments early.
  • Understand the concerns and reservations of various groups towards adopting GLP-1 agonists.

Analysis of Pricing, Accessibility, and Affordability

  • Assess the cost-effectiveness of GLP-1 agonists and their impact on patient affordability.
  • Analyze how pricing structures and market access influence the adoption rates.

Design and Propose Innovative Strategies

  • Develop targeted communication strategies to effectively reach and educate each adopter category.
  • Propose support mechanisms to aid healthcare providers and patients in transitioning to GLP-1 agonists.
  • Suggest policy changes to improve accessibility and affordability of GLP-1 agonists.

Research Questions

  1. What are the primary factors influencing the early adoption of GLP-1 agonists in the Indian market for the management of diabetes and obesity?
  2. How do healthcare providers perceive the efficacy and safety of GLP-1 agonists compared to conventional treatments for diabetes and obesity in India?
  3. What are the attitudes and preferences of diabetic and obese patients towards the use of GLP-1 agonists as a treatment option in India?
  4. What role do pricing structures, accessibility issues, and affordability concerns play in the early adoption of GLP-1 agonists among healthcare providers and patients in India?
  5. How do regulatory policies and market dynamics affect the availability and uptake of GLP-1 agonists in the Indian pharmaceutical market?
  6. What innovative strategies can be designed to overcome the identified barriers and promote the early adoption of GLP-1 agonists in diabetes and obesity management in India?

Research Aims

  1. To identify and analyze the primary factors influencing the early adoption of GLP-1 agonists in the Indian market for the management of diabetes and obesity.
  2. To investigate the perceptions of healthcare providers regarding the efficacy and safety of GLP-1 agonists compared to conventional treatments for diabetes and obesity in India.
  3. To explore the attitudes and preferences of diabetic and obese patients towards the use of GLP-1 agonists as a treatment option in India.
  4. To analyze the role of pricing structures, accessibility issues, and affordability concerns in the early adoption of GLP-1 agonists among healthcare providers and patients in India.
  5. To examine the impact of regulatory policies and market dynamics on the availability and uptake of GLP-1 agonists in the Indian pharmaceutical market.
  6. To design and propose innovative strategies to overcome the identified barriers and promote the early adoption of GLP-1 agonists in diabetes and obesity management in India.

Significance of the Study

This study's significance lies in its potential to enhance the accessibility of anti-diabetic and anti-obesity products in India while fostering a greater understanding and appreciation of GLP-1 among healthcare professionals. By addressing the challenges comprehensively, it can contribute to improving healthcare outcomes and reducing the burden of diabetes and obesity in the Indian population (Ali, 2024; Chen et al., 2024).

Research Design and Methodology

Research Strategy and Eligibility Criteria

This study will adopt a pragmatic philosophy, aiming to take a practical perspective on the various factors influencing the constraints for the adoption of GLP-1 analogs in India. The chosen research approach will be inductive, focusing on identifying barriers to the acceptance of newer molecules in the treatment of diabetes and obesity.

Data Extraction

To achieve comprehensive insights, a mixed-methods approach combining qualitative and quantitative methods will be employed. This will include a thorough secondary literature review along with other appropriate qualitative methods to identify and assess the major hurdles hindering the adoption of new therapies in the context of diabetes and obesity in India.

Quality Assessment and Statistical Analysis

The collected data will undergo a rigorous quality assessment process. Findings from these components will inform the formulation of questionnaire items. This survey questionnaire will be administered to a sample of 300 patients within the diabetic and obese populations in India, aimed at understanding the hurdles for adopting GLP-1 in the Indian market. The collected data will then be meticulously analyzed using advanced statistical techniques such as ANCOVA to discern the key factors responsible for the lack of adoption of GLP-1.

Definition of Terms

  1. Diabetes: A chronic medical condition characterized by elevated levels of blood sugar (glucose) due to either insufficient production of insulin by the pancreas or the body's inability to effectively use insulin. Uncontrolled diabetes can lead to serious complications affecting various organs such as the eyes, kidneys, nerves, and heart.
  2. Obesity: A condition characterized by excessive accumulation of body fat, typically assessed through body mass index (BMI) measurements. It is often associated with various health issues including cardiovascular diseases, diabetes, certain cancers, and musculoskeletal disorders. Obesity results from a combination of genetic, environmental, and behavioral factors.
  3. Self-Pay: This term refers to individuals paying for their medical expenses out-of-pocket, without relying on insurance coverage or third-party payers such as government programs or private insurers. Self-pay patients bear the full financial responsibility for their healthcare services, medications, and treatments.
  4. GLP-1 Analogues (GLP-1 Analogs): Glucagon-like peptide-1 analogs are a class of medications used primarily in the management of type 2 diabetes mellitus. They work by mimicking the action of the naturally occurring hormone GLP-1, which helps regulate blood sugar levels by stimulating insulin secretion, suppressing glucagon release, and promoting feelings of satiety. GLP-1 analogs are administered via injection and are often prescribed in conjunction with other diabetes medications.
  5. New Product Pricing Model: This refers to a strategic approach utilized by businesses to determine the pricing structure for newly introduced products or services. Factors considered in this model include production costs, market demand, competition.

References

Lancet, T. (2023). Diabetes: a defining disease of the 21st century. Lancet (London, England), 401(10394), 2087.

Pradeepa, R., & Mohan, V. (2021). Epidemiology of type 2 diabetes in India. Indian journal of ophthalmology, 69(11), 2932-2938.

Deepa, M., Anjana, R. M., & Mohan, V. (2017). Role of lifestyle factors in the epidemic of diabetes: lessons learnt from India. European journal of clinical nutrition, 71(7), 825-831.

Wong, L. P., Lee, H. Y., Alias, H., Zimet, G., Liu, T., Lin, Y., & Hu, Z. (2024). Cost-based COVID-19 vaccination and willingness to pay: A post-pandemic review. Human Vaccines & Immunotherapeutics, 20(1), 2313860.

Dearing, J. W., & Cox, J. G. (2018). Diffusion of innovations theory, principles, and practice. Health affairs, 37(2), 183-190.

Wang, J. Y., Wang, Q. W., & Yang, X. Y. (2023). GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. Front Endocrinol (Lausanne). 2023; 14: 1085799

Misra A, Khurana L. Obesity-related non-communicable diseases: South Asians vs White Caucasians. Int J Obes (Lond). 2011;35(2):167-187.

Patel D, Kumar A, Patel P, Gyawali B, Mehta D. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes care: a comprehensive review of their safety and efficacy. Diabetes Metab Syndr Obes. 2020;13:893-905.

Prasad K, Dhar R. Emerging trends in cardiovascular diseases in India: lessons from the Covid-19 pandemic. Am J Cardiovasc Drugs. 2021;21(5):459-466.

Ghosal S, Sinha B, Majumder M, et al. Drug pricing policy in India: current trends and future implications. J Pharm Policy Pract. 2016;9:12.

Mohan V, Shah S, Saboo B. Current glycemic status and diabetes related complications among type 2 diabetes patients in India: data from the A1chieve study. J Assoc Physicians India. 2013;61(1 Suppl):12-15.

Chawla R, Madhu S, Makkar B, Ghosh S, Saboo B, Kalra S. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian J Endocrinol Metab. 2020;24(1):1-122.

Nauck, M. A., et al. "GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art. Mol Metab 2021; 46: 101102." (2020).

Lancet, The. "Diabetes: a defining disease of the 21st century." Lancet (London, England) 401.10394 (2023): 2087.

Karunarathna, Indunil, and P. Jayathilaka. "Comprehensive Management of Type 2 Diabetes Mellitus: From Prevention to Novel Therapeutic Approaches." Uva Clinical Lab. Retrieved from Comprehensive Management of Type 2 (2024).

Polonsky, William, et al. "Exploring why people with type 2 diabetes do or do not persist with glucagon-like peptide-1 receptor agonist therapy: a qualitative study." Diabetes Spectrum 34.2 (2021): 175-183.

Karagiannis, Thomas, Eleni Bekiari, and Apostolos Tsapas. "Socioeconomic aspects of incretin-based therapy." Diabetologia 66.10 (2023): 1859-1868.

Chen, Yongru, et al. "Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on “time in range” in patients with type 2 diabetes." Frontiers in Pharmacology 15 (2024): 1370594.

Ali, M. K., Singh, K., Kondal, D., Devarajan, R., Patel, S. A., Shivashankar, R., ... & CARRS Trial Group*. (2016). Effectiveness of a multicomponent quality improvement strategy to improve achievement of diabetes care goals: a randomized, controlled trial. Annals of internal medicine, 165(6), 399-408.

LaMorte, W. W. (2022). Diffusion of Innovation Theory. Boston University School of Public Health.